Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Mineralys Therapeutics announced its second quarter 2026 financial results, including a strengthened balance sheet following a $150 million public offering and a $100 million tranche drawn on a $500 million term loan. The company is on track for FDA's PDUFA target date of December 22, 2026, for lorundrostat, an aldosterone synthase inhibitor target…